Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient’s outcome in advanced colorectal cancer: the CORIOLAN study

@inproceedings{Deleporte2014CorrelatingTM,
  title={Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient’s outcome in advanced colorectal cancer: the CORIOLAN study},
  author={Am{\'e}lie Deleporte and Marianne Paesmans and Camilo Alejandro Garcia and Caroline Vandeputte and Marc Lemort and J. L. Engelholm and Frederic Hoerner and Philippe G. Aftimos and Ahmad Hussein Awada and Nicolas Charette and Godelieve Machiels and Martine J. Piccart and Patrick Flamen and Alain Hendlisz},
  booktitle={BMC Cancer},
  year={2014}
}
Metastatic colorectal cancer (mCRC) may present various behaviours that define different courses of tumor evolution. There is presently no available tool designed to assess tumor aggressiveness, despite the fact that this is considered to have a major impact on patient outcome. CORIOLAN is a single-arm prospective interventional non-therapeutic study aiming mainly to assess the natural tumor metabolic progression index (TMPI) measured by serial FDG PET-CT without any intercurrent antitumor… CONTINUE READING